Diagnosis and Assessment of Hypereosinophilic Syndrome (HES)

OVERVIEW

This is a non-promotional, non-CME disease state educational webcast brought to you by EAACI in collaboration with and paid for by GlaxoSmithKline

This webcast is a 4-part series. The topics focus on HES pathophysiology, HES diagnosis and differential diagnosis, HES complications, and HES multidisciplinary assessment.  HES is a heterogeneous group of rare disorders characterised by blood hypereosinophilia, organ dysfunction or damage attributable to tissue hypereosinophilia. The speakers will provide detail on the pathophysiology of HES, with an overview of the causes and variants of HES; discuss how to investigate HES and differentiate it from other diseases; highlight the complications, signs and symptoms that may be associated with HES; and provide clinical insight on the importance of a multidisciplinary approach for personalised assessment and treatment for patients with HES.

EDUCATIONAL OUTCOME/OBJECTIVES

To gain an understanding and clinical insight into:

• the pathogenic role of eosinophils in HES, the mechanisms resulting in eosinophil expansion and the pathogenic contribution of other cells/mediators to HES
• the diagnosis of HES and identifying the cause, how to rule out other disease when diagnosing HES and identify current markers for HES variants
• the broad spectrum of complications associated with HES, and understand the importance of monitoring organs at risk, variability of complications in different disease variants and the nature of the complication in patients with HES
• improving communication between the primary care physician and specialists and understanding why efficient multidisciplinary patient monitoring and treatment is needed.